Artikel: Implications of NLRP3 Suppression Using Glibenclamide and miR-223 against Colorectal Cancer.
Pharmaceuticals (Basel, Switzerland)
2024 Band 17, Heft 3
Abstract: The NLR family pyrin domain containing 3 (NLRP3) promotes the growth of colorectal cancer (CRC). However, the therapeutic effect of NLRP3 inhibition on CRC cell progression is controversial. This study comparatively investigated the therapeutic effect of ...
Abstract | The NLR family pyrin domain containing 3 (NLRP3) promotes the growth of colorectal cancer (CRC). However, the therapeutic effect of NLRP3 inhibition on CRC cell progression is controversial. This study comparatively investigated the therapeutic effect of a pharmacological NLRP3 inhibitor, glibenclamide (gli), and the post-translational suppression of NLRP3 by miR-223 on CRC cell progression in HCT-116 and HCT-15 cells. LPS and ATP were used to activate Gli-treated and LSB-hsa-miR-223-3p (WT |
---|---|
Sprache | Englisch |
Erscheinungsdatum | 2024-02-26 |
Erscheinungsland | Switzerland |
Dokumenttyp | Journal Article |
ZDB-ID | 2193542-7 |
ISSN | 1424-8247 |
ISSN | 1424-8247 |
DOI | 10.3390/ph17030299 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.